Melissa Sheehan, DO
Family Medicine · Wilmington, DENPI 1417900754
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 408 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,543 and has fallen 80.3% since, to $500 in 2025. Among family medicine clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- GSK$1K
- Astellas Pharma US Inc$728
- Gilead$693
- plus $4K from 30 others
What the payments were for
- Food & beverage$10,90799%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 72 | $2,114 |
| Lilly USA, LLC | 45 | $1,086 |
| Boehringer Ingelheim | 28 | $1,077 |
| GSK | 26 | $1,019 |
| Astellas Pharma US Inc | 39 | $728 |
| Gilead | 28 | $693 |
| AbbVie | 22 | $640 |
| Amgen | 16 | $499 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $441 |
| Merck | 16 | $304 |
| Novo Nordisk | 12 | $274 |
| Bayer | 11 | $251 |
| Johnson & Johnson | 12 | $216 |
| Sanofi-aventis U.S. LLC | 3 | $201 |
| Abbott | 2 | $161 |
| Amarin Pharma, Inc. | 7 | $161 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $120 |
| Novartis | 3 | $120 |
| Eisai Inc. | 1 | $101 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $98 |
| Medtronic | 2 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $83 |
| Pfizer | 5 | $73 |
| Harmony Biosciences LLC | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Viiv Healthcare Company | 2 | $33 |
| Shield Therapeutics Inc | 1 | $28 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Exact Sciences | 1 | $22 |
| Blue Earth Diagnostics | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$824
- FARXIGA$436
- AIRSUPRA$259
- TRELEGY ELLIPTA$249
- UBRELVY$241
- FREESTYLE LIBRE 3$143
- BREZTRI$131
- ANORO ELLIPTA$125
- Otezla$125
- VOQUEZNA$125
- Veozah$125
- QULIPTA$123
- NEXLIZET$120
- NEXLETOL$120
- OFEV$119
- ZEPBOUND$115
- AREXVY$108
- SOLIQUA 100/33$107
- XIFAXAN$103
- Truvada$101
How this compares
$10,977 in reported general payments places this provider in the 90th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $75,363 |
| JanuviaSitagliptin Phosphate | 32 | $50,426 |
| MounjaroTirzepatide | 15 | $24,484 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $22,950 |
| Atorvastatin Calcium | 417 | $4,944 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 36 | $2,940 |
| Rosuvastatin Calcium | 118 | $2,771 |
| Omeprazole | 153 | $2,522 |
| Valsartan | 59 | $1,851 |
| Amlodipine Besylate | 273 | $1,789 |
| Levothyroxine Sodium | 164 | $1,749 |
| Alendronate Sodium | 139 | $1,649 |
| Pravastatin Sodium | 83 | $1,614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,512 |
| Losartan Potassium | 161 | $1,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,077 | $75,36358 claims |
| MerckJanuvia | $304 | $50,42632 claims |
| Lilly USA, LLCMounjaro | $1,086 | $24,48415 claims |
| GSKTrelegy Ellipta | $1,019 | $22,95015 claims |
| AbbVieSynthroid | $640 | $1,00511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 352 family medicine providers in Delaware.
Other family medicine in Wilmington
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
- Glenn HamiltonWilmington$17K
- Lakan Karlo MagatWilmington$16K
- David KrasnerWilmington$16K
- Marc GrobmanWilmington$13K
- Julio NavarroWilmington$13K
- Anna MagatWilmington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.